A Phase I Study to Evaluate the Pharmacokinetics and Safety of Cabotegravir in Adults With Severe Renal Impairment and Healthy Matched Control Participants

This study investigates the impact of severe renal impairment on the pharmacokinetics of cabotegravir, an investigational HIV‐1 integrase inhibitor. This was a phase I, open‐label, parallel‐group, multicenter study conducted in 8 participants with severe renal impairment (creatinine clearance <30...

Descripción completa

Detalles Bibliográficos
Autores principales: Parasrampuria, Ridhi, Ford, Susan L., Lou, Yu, Fu, Caifeng, Bakshi, Kalpana K., Tenorio, Allan R., Trezza, Christine, Spreen, William R., Patel, Parul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618856/
https://www.ncbi.nlm.nih.gov/pubmed/30809978
http://dx.doi.org/10.1002/cpdd.664

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618856/
https://www.ncbi.nlm.nih.gov/pubmed/30809978
http://dx.doi.org/10.1002/cpdd.664

Ejemplares similares